Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 13/20 | 0.45 |
| ▸ | CA2 | P00918 | 13/20 | 0.45 |
| ▸ | CA9 | Q16790 | 10/20 | 0.45 |
| ▸ | CA13 | Q8N1Q1 | 6/20 | 0.45 |
| ▸ | MAOB | P27338 | 5/20 | 0.44 |
| ▸ | MAOA | P21397 | 4/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14938035 | 0.89 | MAOA (0.47) | CA1CA2CA9CA13MAOB | |
| SCHEMBL14938170 | 0.89 | CA9 (0.44) | CA1CA2CA9CA12 | |
| SCHEMBL14938021 | 0.86 | KDM4E (0.43) | CA1CA2CA9KDM4ERAB9A | |
| SCHEMBL14937938 | 0.83 | PTGS2 (0.40) | CA1CA2CA9CA13MAOB | |
| SCHEMBL14938099 | 0.82 | CA12 (0.44) | CA1CA2CA9CA13KDM4E | |
| SCHEMBL14938256 | 0.81 | CA12 (0.42) | CA1CA2CA9CA12 | |
| SCHEMBL14937992 | 0.81 | NTRK1 (0.46) | CA1CA2CA9CA13RAB9A | |
| SCHEMBL14938231 | 0.80 | PTGS2 (0.40) | — | |
| SCHEMBL14938258 | 0.80 | CA12 (0.46) | CA1CA2CA9CA12 | |
| SCHEMBL14938224 | 0.78 | CA12 (0.43) | CA1CA2CA9CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8642626-B2 | Ethinyl-pyrazole derivative | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2014-02-04 | — | — | US | disclosed |
| US-8642626-B2 | Ethinyl-pyrazole derivative | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2014-02-04 | — | — | US | disclosed |
| US-8642626-B2 | Ethinyl-pyrazole derivative | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2014-02-04 | — | — | US | disclosed |
| EP-2599775-A1 | ETHINYL-PYRAZOLE DERIVATIVE | Taisho Pharmaceutical Co., Ltd. (JP) | 2013-06-05 | — | — | EP | disclosed |
| US-20130123500-A1 | ETHINYL-PYRAZOLE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2013-05-16 | — | — | US | disclosed |
| US-20130123500-A1 | ETHINYL-PYRAZOLE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2013-05-16 | — | — | US | disclosed |
| US-20130123500-A1 | ETHINYL-PYRAZOLE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2013-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123500-A1 | ETHINYL-PYRAZOLE DERIVATIVE | GABRE, GRIN3A, GRIK5 | CA1 2027/4885CA2 3016/4885CA9 4467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.